Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
30 août 2023 08h30 HE
|
Veru Inc.
MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral...
Veru Reports Fiscal 2023 Third Quarter Financial Results
10 août 2023 06h30 HE
|
Veru Inc.
Company receives further regulatory clarity from FDA on Phase 3 ENABLAR-2 study. Potential for enobosarm +/- abemaciclib accelerated approval pathway in metastatic breast cancer, if successful based...
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
03 août 2023 08h30 HE
|
Veru Inc.
MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for breast cancer and for viral acute...
Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
21 juin 2023 08h30 HE
|
Veru Inc.
Research grants from U.S. Department of Defense (DoD) and National Cancer Institute’s Research Project Grant (NCI R01) awarded to UTHSC to study new types of targeting agents for multiple cancer...
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
01 juin 2023 08h30 HE
|
Veru Inc.
MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and...
Veru to Present at the Jefferies Healthcare Conference
24 mai 2023 08h30 HE
|
Veru Inc.
MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for...
Veru Reports Fiscal 2023 Second Quarter Financial Results
11 mai 2023 06h30 HE
|
Veru Inc.
Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS),...
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
04 mai 2023 08h30 HE
|
Veru Inc.
Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all...
Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
03 mai 2023 08h30 HE
|
Veru Inc.
MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for...
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
27 avr. 2023 06h45 HE
|
Veru Inc.
MIAMI, FL, April 27, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related...